Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 12-Month Low – Time to Sell?

Posted by Stanley Muller on Sep 17th, 2026

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $22.50 and last traded at $22.81, with a volume of 825544 shares traded. The stock had previously closed at $22.75.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Truist Financial assumed coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set a “buy” rating and a $49.00 price target for the company. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Leerink Partners initiated coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Piper Sandler restated a “neutral” rating and set a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

Read Our Latest Research Report on Collegium Pharmaceutical

Collegium Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The stock has a market capitalization of $722.51 million, a P/E ratio of 17.90 and a beta of 0.72. The company has a fifty day moving average of $29.68 and a two-hundred day moving average of $32.96.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.Collegium Pharmaceutical’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.68 EPS. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.19 EPS for the current year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth $536,000. Squarepoint Ops LLC lifted its position in shares of Collegium Pharmaceutical by 124.8% in the 2nd quarter. Squarepoint Ops LLC now owns 47,897 shares of the specialty pharmaceutical company’s stock worth $1,734,000 after buying an additional 26,589 shares during the last quarter. Corient Private Wealth LP boosted its holdings in shares of Collegium Pharmaceutical by 60.5% in the 2nd quarter. Corient Private Wealth LP now owns 71,870 shares of the specialty pharmaceutical company’s stock valued at $2,603,000 after buying an additional 27,097 shares during the period. Amundi boosted its holdings in shares of Collegium Pharmaceutical by 188.0% in the 2nd quarter. Amundi now owns 23,492 shares of the specialty pharmaceutical company’s stock valued at $850,000 after buying an additional 15,336 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Collegium Pharmaceutical during the 2nd quarter valued at about $295,000.

Collegium Pharmaceutical Company Profile

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.